NPC43

NPC43 is a non-peptidyl small molecule and selenium-containing nucleoside analog that functions as a direct agonist of the insulin receptor (INSR). Unlike traditional insulin therapies, NPC43 is capable of activating INSR signaling and its downstream targets in the complete absence of insulin by interacting directly with the INSRα subunit. Preclinical studies in Leprdb/db mouse models of type 2 diabetes have shown that the compound is orally bioavailable and effectively reduces hyperglycemia and hyperinsulinemia. Crucially, NPC43 exhibits selectivity for INSR over the insulin-like growth factor 1 receptor (IGF-1R), which may mitigate risks associated with IGF-1R-mediated mitogenesis. It is being explored as a potential oral or injectable insulin replacement therapy for the management of type 2 diabetes and other insulin-resistant states.

Other names

adenosine, 5'-Se-methyl-5'-seleno-, 2',3'-diacetatenon-peptidyl compound #43